Core Viewpoint - The public fund market is currently experiencing two significant trends: a surge in limit purchases for high-performing active equity funds and a wave of self-purchases by public fund institutions to bolster market confidence [2][8]. Limit Purchases - Numerous high-performing active equity funds have announced limits on purchases, with over a hundred funds implementing such measures since the beginning of the second half of the year [2][5]. - For instance, China Europe Fund announced limits on large purchases for its medical innovation stock fund and other funds, citing the need to ensure stable operations and protect the interests of existing fund holders [4][5]. - The performance of these funds has been impressive, with some, like the China Europe Medical Innovation Stock Fund, achieving over 60% net value growth year-to-date [5][6]. Self-Purchases - Public fund institutions, including Southern Fund and Industrial Bank of China Credit Fund, have initiated significant self-purchases of their equity funds, with Southern Fund planning to invest at least 230 million yuan [7][8]. - This self-purchase trend is seen as a positive signal, indicating that institutions remain optimistic about the market's future, especially as the Shanghai Composite Index stabilizes above 3600 points [8]. - The self-purchases not only serve as a confidence endorsement but also create a deeper capital bond between the institutions and their funds, promoting a long-term investment philosophy [8].

Group 1 - The core viewpoint of the articles is that several funds managed by China Universal Asset Management have announced purchase limits to ensure stable operations and protect the interests of fund holders [1][2][9] - China Universal Medical Innovation Fund, managed by Guo Lan, will limit single account purchases to 100,000 yuan starting August 11 [3][4] - The China Universal Science and Technology Theme Fund, managed by Shao Jie, will also impose a limit on large purchases over 1 million yuan from August 11 [6][7] Group 2 - As of the end of Q2, the China Universal Medical Innovation Fund had a scale of 8.114 billion yuan, reflecting a nearly 20% increase year-on-year, with a one-year return of 80.12%, ranking in the top 2 of its category [4][5] - The fund manager, Guo Lan, maintains a positive outlook on the innovative drug sector, citing increasing global competitiveness of domestic companies and supportive domestic policies [5] - The China Universal Science and Technology Theme Fund has a one-year return of 84.33%, also ranking in the top 2 of its category, benefiting from the explosive growth in the technology sector [7][8] Group 3 - The recent trend of fund purchase limits is seen across the industry, with approximately 50 actively managed equity funds announcing similar restrictions since July [10][11] - The rationale behind these limits is to control fund size, maintain investment strategy effectiveness, and protect existing investors from potential losses due to market volatility [10][11] - Fund managers are increasingly focusing on stable growth and the long-term profitability of their products rather than short-term performance spikes [11]